Cargando…
Study comparing the efficacy and renal safety for patients with diabetes switching from dapagliflozin to empagliflozin
Background Previously, dapagliflozin was limited to patients with an estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m(2), while empagliflozin can be used for those with an eGFR ≥ 45 mL/min/1.73 m(2). Therefore dapagliflozin was switched to empagliflozin in many patients when eGFR decre...
Autores principales: | Yang, Ai-Yu, Chen, Hung-Chun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352843/ https://www.ncbi.nlm.nih.gov/pubmed/33258006 http://dx.doi.org/10.1007/s11096-020-01210-1 |
Ejemplares similares
-
Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes
por: Yang, Ai-Yu, et al.
Publicado: (2022) -
Comparison of safety and efficacy of dapagliflozin and empagliflozin in type 2 diabetes mellitus patients in India
por: Varshney, Amit, et al.
Publicado: (2023) -
Clinical Parameters Affecting the Therapeutic Efficacy of SGLT-2—Comparative Effectiveness and Safety of Dapagliflozin and Empagliflozin in Patients with Type 2 Diabetes
por: Anton, Irina Claudia, et al.
Publicado: (2022) -
Renal and Glucose-Lowering Effects of Empagliflozin and Dapagliflozin in Different Chronic Kidney Disease Stages
por: Lin, Yi-Hsuan, et al.
Publicado: (2019) -
Dapagliflozin versus empagliflozin in patients with chronic kidney disease
por: Alnsasra, Hilmi, et al.
Publicado: (2023)